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The alkenylbenzene estragole is a constituent of several herbs and 
spices. It induces hepatomas in rodents at high doses following bio-
activation by cytochrome P450s and sulfotransferases (SULTs) giv-
ing rise to the ultimate carcinogenic metabolite 1'-sulfooxyestragole 
which forms DNA adducts. Methanolic extracts from different 
alkenylbenzene-containing herbs and spices were able to inhibit 
SULT activity. Flavonoids including quercetin, kaempferol, myri-
cetin, apigenin, and nevadensin were the major constituents 
responsible for this inhibition with Ki values in the nano to micro-
molar range. In human HepG2 cells exposed to the proximate 
carcinogen 1ʹ-hydroxyestragole, the various flavonoids were able 
to inhibit estragole DNA adduct formation and shift metabolism 
in favor of glucuronidation which is a detoxification pathway for 
1ʹ-hydroxyestragole. In a next step, the kinetics for SULT inhibi-
tion were incorporated in physiologically based biokinetic (PBBK) 
models for estragole in rat and human to predict the effect of 
co-exposure to estragole and (mixtures of) the different flavonoids on 
the bioactivation in vivo. The PBBK-model-based predictions indi-
cate that the reduction of estragole bioactivation in rat and human 
by co-administration of the flavonoids is dependent on whether the 
intracellular liver concentrations of the flavonoids can reach their Ki 
values. It is expected that this is most easily achieved for nevadensin 
which has a Ki value in the nanomolar range and is, due to its methyl-
ation, more metabolically stable than the other flavonoids.
Key Words:  estragole; bioactivation; sulfotransferase inhibi-
tor; flavonoid; matrix; physiologically based biokinetic (PBBK) 
modeling.
Herbs and spices have a long history of use as food, flavoring 
and coloring agents throughout the world (Dearlove et  al., 
2008; Smith et al., 2002). In culinary usage, herbs are most 
commonly seasonings derived from leaves of plants. Spices, 
in contrast, are obtained from seeds, berries, fruits, barks, 
or roots (Dearlove et  al., 2008). Alkenylbenzenes such as 
estragole (1-allyl-4-methoxybenzene), present in the volatile 
oils, contribute to the characteristic taste and fragrance of 
many herbs and spices including nutmeg, basil, anise, mace, 
tarragon, fennel, and pimento (Smith et al., 2002). Oral intake 
of estragole results primarily from consumption of foods, 
mainly herbs and spices, and of their essential oils. Based 
on rodent studies, estragole was found to be genotoxic and 
carcinogenic (Drinkwater et  al., 1976; Miller, 1983). Based 
on these findings, the use of estragole as a pure substance in 
foodstuffs has been prohibited since September 2008 within 
the European Union (Regulation [EC] No 1334/2008 of the 
European Parliament and of the Council of 16 December 
2008). Realistic daily intake levels of estragole have been 
estimated to range from 0.01 mg/kg bw/day (Smith et  al., 
2002) to 0.07 mg/kg bw/day (SCF, 2001). Given that at present 
addition of estragole as a pure compound to individual food 
categories is no longer allowed, the value of 0.01 mg/kg bw/
day resulting mainly from herbs and spices (Smith et  al., 
2002)  is taken in the present study as the value for current 
levels of dietary human intake.
Figure  1 presents an overview of the bioactivation and 
detoxification pathways of estragole. Based on in vivo stud-
ies, at low doses (<10 mg/kg bw), O-demethylation appears 
to be more favored in humans and in rodents and yields phen-
olic derivatives which are to a large extent excreted as the 
sulfate or glucuronic acid conjugate (Anthony et  al., 1987; 
Sangster et  al., 1987). Bioactivation of estragole proceeds 
by 1ʹ-hydroxylation to 1ʹ-hydroxyestragole and subsequent 
sulfonation to 1ʹ-sulfooxyestragole. The sulfate conjugate 
of 1ʹ-hydroxyestragole is unstable and hydrolyzes to form a 
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reactive electrophilic intermediate (carbocation ion) which 
has been linked to glutathione (GSH) depletion, oxidative 
stress, protein-, DNA-, and GSH-adduct formation, prob-
ably at or near the site of formation (Phillips et  al., 1981; 
Smith et  al., 2002). Therefore, the sulfate conjugate of 
1ʹ-hydroxyestragole is considered to be the ultimate hepato-
toxic and hepatocarcinogenic agent in rodents (Boberg et al., 
1983). This conclusion was corroborated by co-administration 
of the specific sulfotransferase (SULT) inhibitor pentachloro-
phenol (PCP), which resulted in a potent inhibition of hepatic 
tumor induction by long-term dietary administration of the 
closely related alkenylbenzenes safrole or 1ʹ-hydroxysafrole 
and a significant decrease of SULT activity and hepatic DNA 
and RNA adduct formation by 1ʹ-hydroxysafrole in mice 
(Boberg et al., 1983).
A significant difficulty in evaluating the metabolic, 
biochemical, and toxicological data for estragole as well 
as other alkenylbenzenes is that human exposure to these 
substances results from exposure to a complex mixture 
of food, spice, and spice oil constituents which may 
significantly impact the biochemical fate and toxicological 
risk of the alkenylbenzenes. In this respect, we have previously 
demonstrated that a methanolic extract from basil, which 
contained estragole, also contained the flavone nevadensin 
(5,7-dihydroxy-6,8,4ʹ-trimethoxyflavone) which was able to 
inhibit DNA-adduct formation in rat hepatocytes exposed to the 
proximate carcinogen 1ʹ-hydroxyestragole (Alhusainy et  al., 
2010; Jeurissen et al., 2008). This inhibition by nevadensin was 
shown to occur at the level of SULT-mediated bioactivation of 
1ʹ-hydroxyestragole (Alhusainy et  al., 2010; Jeurissen et  al., 
FIG. 1. Bioactivation and detoxification pathways of estragole.
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2008). Altogether, the results of our previous research point 
at a reduction of DNA-adduct formation and consequently 
a potential reduction of cancer risk when estragole exposure 
occurs within a food matrix containing SULT inhibitors 
compared with what is observed upon exposure to pure 
estragole. Given these previous results, the objectives of the 
present study were (1) to identify the presence and nature 
of possible SULT inhibitors able to interfere with estragole 
bioactivation in other alkenylbenzene-containing botanical 
preparations and (2) to predict the possible effects of combined 
exposure to a mixture of SULT inhibitors on formation levels of 
the ultimate carcinogen 1ʹ-sulfooxyestragole at physiologically 
relevant concentrations by incorporating the kinetics for SULT 
inhibition by the compounds in the mixture into our recently 
developed physiologically based biokinetic (PBBK) models for 
estragole in the liver of rat (Punt et al., 2008) and human (Punt 
et al., 2009).
MATERIALS AND METHODS
Materials and chemicals. 1ʹ-Hydroxyestragole and 1ʹ-acetoxyestragole 
are genotoxic and carcinogenic compounds and caution should be taken when 
handling them. Twelve dried herbs and spices were purchased from local super-
markets: nutmeg and mace (Myristica fragrans Houtt.), star anise (Illicium 
verum Hook. f.), parsley (Petroselinum crispum (Mill.) Nyman ex A.W. Hill), 
pimento/allspice (Pimenta dioica (L.) Merr.), cinnamon (Cinnamomum zeylani-
cum J. Presl.), dill (Anethum graveolens L.), laurel (Laurus nobilis L.), tarragon 
(Artemisia dracunculus L.), fennel (Foeniculum vulgare Mill.), anise (Pimpinella 
anisum L.), and basil (Ocimum basilicum L.). 7-Hydroxycoumarin (7HC; 99%), 
7-hydroxycoumarin sulfate (7HCS; 99%), quercetin, kaempferol, myricetin, api-
genin, luteolin, 3ʹ-phosphoadenosine-5ʹ-phosphosulfate (PAPS), GSH, uridine 
5ʹ-diphosphoglucuronic acid (UDPGA), and fetal bovine serum were obtained 
from Sigma Aldrich (Steinheim, Germany). Nicotinamide adenine dinucleotide 
(NAD+) was obtained from Roche Diagnostics (Mannheim, Germany).
Nevadensin was purchased from Apin Chemicals (Milton, U.K.). 
Trifluoroacetic acid was obtained from Mallinckrodt Baker B.V. (The 
Netherlands). Methanol (Ultra Liquid Chromatography/Mass Spectrometry, 
ULC/MS) and acetonitrile (ULC/MS) were obtained from Biosolve 
(Valkenswaard, The Netherlands), and pro-analysis grade acetic acid was 
purchased from VWR (Darmstadt, Germany). Hanks Balanced Salt Solution 
(HBSS), PBS, and gentamicin were purchased from Gibco (Paisley, U.K.). 
DMEM-F12 L-glutamine medium, tris-hydroxymethylaminomethane 
(tris), and trypsin were obtained from Invitrogen (Breda, The Netherlands). 
Dimethyl sulfoxide (DMSO), spectroscopic grade (99.9%) was supplied by 
Acros Organics (Geel, Belgium). Pooled male rat (Sprague Dawley), pooled 
human liver S9, and microsomal homogenates were obtained from BD Gentest 
(Woburn, MA), and PCP (98%) was obtained from Sigma-Riedel de Haen 
(Seelze, Germany). Nanopure water was obtained from a Barnstead Nanopure 
Type I  ultrapure water system. 1ʹ-Hydroxyestragole was synthesized as 
described previously by Drinkwater et al. (1976) based on a method described 
for the synthesis of 1ʹ-hydroxysafrole (Borchert et al., 1973). Structural confir-
mation by Gas Chromatography-Mass Spectrometry (GC-MS) was carried out 
as described previously (Punt et al., 2007).
Preparation of methanolic herb and spice extracts. Methanolic herb and 
spice extracts were prepared according to the method described previously 
(Alhusainy et al., 2010; Jeurissen et al., 2008). In short, herb and spice extracts 
were prepared by stirring 5 g of dried herb or spice twice for 2 h at room tem-
perature, each time with 100 mL of a mixture of methanol, ultra-pure water, and 
acetic acid (ratio 80:19:1). The extracts obtained were filtered using a folded 
filter (Schleicher & Schuell), and the pooled filtrates were evaporated to dryness 
under vacuum using a Rotavapor apparatus (Heidolph Laborota 4000 efficient). 
Star anise was first minced using a pair of scissors, and then using a pestle and 
mortar to obtain an efficient extraction yield. The extraction yield for the differ-
ent herbs and spices ranged between 18 and 49% (w/w). Afterwards, the dried 
extracts were dissolved in methanol to achieve three concentrated extract stocks 
(2, 5, and 20 mg/ml) as described previously (Alhusainy et al., 2010).
Measurement of SULT activity. SULT activity and its inhibition by dif-
ferent herb and spice extracts (nutmeg, mace, star anise, parsley, pimento/
allspice, cinnamon, dill, laurel, tarragon, fennel, anise, and basil) were quan-
tified using the standard substrate 7-hydroxycoumarine (7HC) in line with 
our previous work (Alhusainy et  al., 2010). Unlike the sulfonated metabo-
lite of 1ʹ-hydroxyestragole, the metabolite resulting from the sulfonation of 
7HC is stable in aqueous solution and can be detected and quantified by High 
Performance Liquid Chromatography-Ultraviolet detection (HPLC-UV) as 
described previously (Alhusainy et al., 2010; Wang et al., 2006).
Identification of SULT inhibitors in alkenylbenzene-containing herbs and 
spices. The methanolic herb and spice extracts which resulted in the most 
potent inhibition of SULT activity were fractionated using HPLC–UV, and the 
fractions obtained were tested for their effect on SULT activity as described in 
our previous work (Alhusainy et al., 2010). The compounds in the most active 
fractions were identified based on comparison of their UV spectra and retention 
time to the UV spectra and the retention time of commercially available refer-
ence compounds. In addition, a literature review was made to screen for major 
SULT inhibitors present in these alkenylbenzene-containing herbs and spices.
Kinetics for inhibition of SULT-catalyzed conversion of 7HC into 7HCS and 
of oxidation and glucuronidation of 1ʹ-hydroxyestragole into 1ʹ-oxoestragole 
and 1ʹ-hydroxyestragole glucuronide by selected flavonoids. The K
i
 for SULT 
inhibition was determined by performing incubations for SULT activity with 
pooled male rat liver S9 fractions in the presence of increasing concentrations 
of 7HC (0–100 µM) in the absence or presence of 0.75 µM quercetin, 0.3 µM 
kaempferol, 5 µM myricetin, or 0.35 µM apigenin. These flavonoid concentra-
tions were selected because they were close to the identified inhibitory concen-
tration 50% (IC
50
) values determined with pooled male rat liver S9 fractions (data 
not shown). Incubations were performed as described previously (Alhusainy 
et al., 2010). The possible effects of the identified SULT inhibitors on the detox-
ification of 1ʹ-hydroxyestragole by glucuronidation and oxidation (Figure  1) 
were quantified in vitro as well. The K
i
 for the inhibition of 1ʹ-hydroxyestragole 
oxidation was determined by performing incubations with pooled human liver 
microsomes in the presence of increasing concentrations of 1ʹ-hydroxyestragole 
(0–1000 µM) in the absence or presence of 5 µ M quercetin, 5 µM kaempferol, 
10 µM myricetin, and 10 µM apigenin. These flavonoid concentrations were 
selected because they were close to the identified IC
50
 values determined with 
pooled human liver microsomal fractions (data not shown). Incubations were 
performed as previously described (Alhusainy et al., 2010). Subsequently, the 
maximum velocity (V
max
), the Michaelis–Menten constant (K
m
), and the inhibi-
tion constant (K
i
) for the formation of 7HCS and 1ʹ-oxoestragole were deter-
mined as described below (Data Analysis). Incubations for testing the effect of 
the identified SULT inhibitors on 1ʹ-hydroxyestragole glucuronidation were also 
performed. In short, the effect of the identified botanical constituents querce-
tin, kaempferol, myricetin, and apigenin on 1ʹ-hydroxyestragole glucuronida-
tion was examined with pooled human liver microsomes. The incubations were 
performed as described previously (Alhusainy et al., 2010; Punt et al., 2009) in 
the absence or presence of each respective flavonoid up to a concentration of 
80 µM and at 1000 µM of 1ʹ-hydroxyestragole (a concentration close to the K
m
 
value determined by Punt et al. (2009) for the formation of 1ʹ-hydroxyestragole 
glucuronide by pooled human liver microsomes), both added from 200 times 
concentrated stock solutions in DMSO.
Effect of flavonoid mixtures on SULT activity and on oxidation of 
1ʹ-hydroxyestragole. Incubations for testing the SULT inhibition by a mix-
ture of quercetin, kaempferol, apigenin, and nevadensin (each flavonoid added 
from a 400 times concentrated stock solution in DMSO) were performed using 
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pooled male rat liver S9 fractions at concentrations equal to 0K
i
 (DMSO con-
trol), 0.2K
i
, 0.5K
i
, 1K
i
, 2K
i
, 5K
i
, or 10K
i
 of each flavonoid together with 25 µM 
of the substrate 7HC with incubation conditions similar to what was described 
previously (Alhusainy et al., 2010). Incubations for testing inhibition of con-
version of 1ʹ-hydroxyestragole to 1ʹ-oxoestragole by a mixture of quercetin, 
kaempferol, myricetin, and apigenin were performed using pooled human 
liver microsomes. These flavonoids were added to the incubation mixtures 
from 400 times concentrated stock solutions in DMSO at final concentrations 
equal to 0K
i
 (DMSO control), 0.1K
i
, 0.2K
i
, 0.5K
i
, 1K
i
, or 2K
i
 of each flavonoid 
together with 400 µM of the substrate (a concentration close to the K
m
 value 
determined by Punt et al. (2009) for the conversion of 1ʹ-hydroxyestragole to 
1ʹ-oxoestragole by pooled human liver microsomes) using incubation condi-
tions similar to what was described previously (Alhusainy et al., 2010).
Cultivation and treatments of HepG2  cells. A total of approximately 
1 × 106 HepG2 cells/well were seeded in a six-well plate with each well con-
taining DMEM/F12 medium containing GlutaMax, 10% fetal bovine serum, 
and 50 µg/ml gentamycin and incubated in a humidified incubator, 5% CO
2
 and 
95% air at 37°C until confluent monolayers were obtained. Then, cells were 
washed with HBSS. Cytotoxicity of the test compounds was evaluated using 
the MTT test (Hussain et al., 1993). For testing detoxification and bioactivation 
of 1ʹ-hydroxyestragole in response to different flavonoid treatments, cells were 
exposed to 50 µM 1ʹ-hydroxyestragole, added from a 1000 times concentrated 
stock solution in DMSO, in the absence or presence of the flavonoid mixtures. 
All flavonoids when tested individually or in a mixture (Table 4) were added 
individually from 800 times concentrated stock solutions in DMSO to DMEM/
F12 containing GlutaMax and 50 µg/ml gentamicin and incubations were per-
formed for 22 h at 37°C in a humidified atmosphere. To measure the effect of 
the different flavonoids or their mixtures on the formation of the major DNA 
adduct N2-(trans-isoestragole-3ʹ-y1)-2ʹ-deoxyguanosine (E-3ʹ-N2-dGuo), cells 
were scraped in PBS and the cells of six wells were pooled in an Eppendorf 
vial and centrifuged at 6000 rpm for 5 min (Eppendorf centrifuge, type 5415C, 
Hamburg, Germany) to obtain pellets. The pellets were stored at −20°C until 
DNA isolation using a Dojindo Get pure DNA Kit Cell, Tissue kit (Dojindo, 
Amsterdam, The Netherlands), according to the accompanying protocol. 
Extraction, digestion, and quantification of E-3ʹ-N2-dGuo were performed as 
previously described (Paini et al., 2010).
Identification, analysis, and quantification of metabolites. Identification 
and analysis of 7HCS, 1ʹ-hydroxyestragole glucuronide, and 1ʹ-oxoestragole 
by HPLC–UV and their quantification by calibration curves using available 
standards was performed as described in our previous work (Alhusainy et al., 
2010; Punt et al., 2008, 2009). Detection and quantification of the major DNA 
adduct N2-(trans-isoestragole-3ʹ-y1)-2ʹ-deoxyguanosine (E-3ʹ-N2-dGuo) 
by Liquid Chromatography Electrospray Ionization Mass Spectrometry 
(LC-ESI-MS/MS) was performed as previously described (Paini et al., 2010).
Estragole PBBK model. To obtain insight in the quantitative dose- and 
species-dependent effects of the flavonoid inhibitors on the formation of the 
ultimate carcinogenic metabolite 1ʹ-sulfooxyestragole, in the target organ, 
the liver, we modified our previously developed PBBK models to take the 
inhibition into account. Supplementary figure  1 presents the basic concept 
of these models, which were originally developed to simulate the bioactiva-
tion, and detoxification of estragole in both rat (Punt et al., 2008) and human 
(Punt et  al., 2009). The original models were described in detail previously 
(Punt et al., 2008, 2009) and include separate compartments for liver, lung, and 
kidney, representing organs which were found to be involved in the metabol-
ism of estragole. A separate compartment for fat tissue was included in order 
to take into account the relatively higher partition coefficient of estragole 
in fat tissue. All other tissues were lumped into either a rapidly perfused or 
slowly perfused tissue group (Ramsey and Andersen, 1984). The physiological 
parameters were obtained from literature (Brown et al., 1997; Supplementary 
table 1). The partition coefficients were estimated from the log Kow based on 
a published method (DeJongh et al., 1997). Log Kow values were estimated 
using the software package ClogP version 4.0 (Biobyte, Claremont, CA) and 
amounted to 3.1 for estragole and 1.6 for 1ʹ-hydroxyestragole (Supplementary 
TABLE 1 
Flavonoids Present in Some Alkenylbenzene-containing Herbs 
and Spices Based on Literature
Herb
Major flavonoids identified 
in herbs and spices based 
on literature and their 
amounts References
Basil (Ocimum basilicum 
L.) 
Nevadensin (3.78–43.47)b (Grayer et al., 2004)
Apigenin (0.48–2.14)b (Grayer et al., 2004)
Luteolin (0.48–0.78)b (Grayer et al., 2004)
Catechinc (Shan et al., 2005)
Pimento (Pimenta dioica 
(L.) Merr.)
Quercetin and myricetinc (Kikuzaki et al., 2008)
Nutmeg (Myristica 
fragrans Houtt.)a
Catechinc (Shan et al., 2005)
Quercetin and kaempferolc (Suhaj, 2006)
Dill (Anethum graveolens 
L.)
Quercetin (48–110)d (Justesen and Knuthsen, 
2001)
Kaempferol (16–24)d (Suhaj, 2006)
Tarragon (Artemisia 
dranunculus L.)
Quercetin (10)d (Justesen and Knuthsen, 
2001)
Kaempferol (11)d (Justesen and Knuthsen, 
2001)
Luteolin (1)d (Justesen and Knuthsen, 
2001)
Parsley (Petroselinum 
crispum (Mill.) Nyman ex 
A.W. Hill)
Quercetin (0–1)d (Justesen and Knuthsen, 
2001)
Apigenin (510–630)d (Justesen and Knuthsen, 
2001)
Luteolin (0–4)d (Justesen and Knuthsen, 
2001)
aNutmeg is the actual seed of the tree, whereas mace is the dried “lacy” 
 reddish covering or aril of the seed.
bAmounts expressed as percentages of total flavones.
cAmounts are not reported.
dAmounts expressed as (mg/100 g fresh weight).
TABLE 2 
Kinetic Parameters of SULT-dependent Formation of 7HCS by 
Pooled Male Rat Liver S9 in the Absence or Presence of Different 
Flavonoids
Inhibitor
Apparent V
max
(nmol/min/mg 
protein)a
Apparent K
m
(µM)
K
i
b
(µM)
Quercetin
(0.75 µM)
1.8 ± 0.1* 4.3 ± 0.6 1.5
Kaempferol
(0.3 µM)
1.8 ± 0.2* 4.0 ± 1.1 0.6
Myricetin
(5 µM)
1.9 ± 0.01* 3.8 ± 0.3 11.9
Apigenin
(0.35 µM)
1.8 ± 0.1* 3.5 ± 0.6 0.7
aProtein from pooled male rat liver S9.
bCalculated using the Michaelis–Menten equation for noncompetitive inhibi-
tion (Vapp
max
 = V
max
/(1+([I]/K
i
)), where [I] is the flavonoid concentration (µM). 
An asterisk (*) indicates a significant inhibition compared with the incubation 
without inhibitor (p < 0.001).
Note. The control (no inhibitor) values were: V
max
 = 2.7 ± 0.2 nmol/min/mg 
S9 protein, and K
m
 = 4.0 ± 1.0 µM.
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table  2). The apparent V
max
 values for the different phase I  and II reactions, 
expressed as nmol/min (mg microsomal or S9 protein)−1 were determined in 
vitro and were scaled to the liver using a microsomal protein yield of 32 mg/g 
liver (Barter et  al., 2007)  or using an S9 protein yield of 143 mg/g liver 
(Medinsky et al., 1994; Supplementary table 2). The apparent K
m
 values were 
also determined in vitro and were assumed to correspond to the apparent in vivo 
K
m
 values. The absorption rate constant (Ka) was set to 1.0/h, resulting in a 
rapid absorption of estragole from the gastrointestinal tract with an absorption 
half-life of 0.7 h (Anthony et al., 1987; Supplementary table 2). Mass balance 
equations were applied to describe the Absorption, Distribution, Metabolism, 
Excretion (ADME) of estragole in the different tissue compartments, and the 
kinetic parameters for the different bioactivation and detoxification reactions 
of estragole were based on in vitro kinetic data obtained using relevant rat and 
human tissue fractions. A full description of the mass balance equations can be 
found in our previous papers (Punt et al., 2008, 2009). Model equations were 
coded and numerically integrated in Berkeley Madonna 8.0.1 (Macey and Oster, 
UC Berkeley, CA, USA) using the rosenbrock’s algorithm for stiff systems. The 
predictions of the PBBK model for male rat (Punt et al., 2008) for the formation 
of 4-allylphenol and 1ʹ-hydroxyestragole glucuronide were in good agreement 
with observations in the literature in female Wistar rats in vivo (Anthony et al., 
1987), and the PBBK model for human (Punt et al., 2009) could predict levels 
of the same metabolites within the same order of magnitude compared with the 
reported levels in vivo in two human volunteers (Sangster et al., 1987).
The uptake of estragole from the gastrointestinal tract in the PBBK models 
is described by a first-order process, assuming direct entry from the intestine to 
the liver compartment; thus, uptake of estragole into the liver is set at 100% in 
line with what is described in literature for estragole (Punt et al., 2008, 2009; 
Sangster et al., 1987).
In the present study, the PBBK models developed by Punt et  al. (2008, 
2009) for rat and human were modified as described below to take the flavo-
noid inhibition into account. The modified models were subsequently used to 
predict the effect of three different flavonoid scenarios (Table 5), representing 
relevant dietary flavonoid intakes, on the formation of the ultimate carcinogenic 
metabolite 1ʹ-sulfooxyestragole using an estragole dose of 0.01 mg/kg bw/day, 
representing the estragole dose considered relevant for human dietary exposure 
from herbs and spices mainly (Smith et al., 2002). Only flavonoids which had 
an effect on SULT activity, as well as on oxidation of 1ʹ-hydroxyestragole, 
were included in the first two scenarios (Table 5). The modified models did 
not include submodels for ADME characteristics of each flavonoid inhibitor. 
Rather, as a first approximation, each flavonoid included was assumed to fol-
low a similar time-dependent concentration curve in the liver of rat and human 
as that of estragole. To make the link between the external dose of compounds 
and the internal dose in the liver, the molar ratio (L) between estragole at a 
dose of 0.01 mg/kg bw/day and each SULT inhibitor was calculated based on 
the relevant intake scenarios in Table 5 and assumed to be maintained in the 
liver by keeping the molar ratio (L) between estragole and each flavonoid con-
stant during the modeling time (24 h). This was represented in the model using 
the following equation: [I]=CL
E
 × L × f, where [I] is flavonoid concentration 
(µmol/l), CL
E
 is the concentration of estragole in the liver (µmol/l), L is the 
molar ratio between estragole and each SULT inhibitor which is calculated 
based on an estragole dose of 0.01 mg/kg bw/day and the relevant intake sce-
nario of flavonoid(s) (Table 5). To obtain some insight into the effects resulting 
from differences in kinetics and uptake of estragole on the one hand and the 
flavonoids on the other hand, the product of CL
E
 × L was multiplied with the 
factor (f) which varied from 0 to 1. Thus, when f equals 0, this represents no 
uptake of the flavonoid into the liver, whereas when f equals 1, this represents 
a 100% uptake of the flavonoid into the liver. The Michaelis–Menten equation 
representing the sulfonation or oxidation of 1ʹ-hydroxyestragole in the pres-
ence of a single inhibitor was as follows:
dAM
HES
/dt = V
max,L-HES
/(1+([I]/K
i
))*CL
HE
/PL
HE
/(K
m,L-HES 
+(CL
HE
/PL
HE
)) 
and
dAM
HEO
/dt = V
max,L- HEO
/(1+([I]/K
i
))*CL
HE
/PL
HE
/(K
m,L-HEO
+(CL
HE
/PL
HE
))
where dAM
HES
/dt is the rate of 1ʹ-sulfooxyestragole formation in µmol/h) and 
dAM
HEO
/dt is the rate of 1ʹ-oxoestragole formed µmol/h), V
max,L-HES
 is the maxi-
mum rate of formation of 1ʹ-sulfooxyestragole, V
max,L-HEO
 is the maximum rate 
of formation of 1ʹ-oxoestragole, [I] is the concentration of quercetin (second 
scenario, Table 5) or nevadensin (third scenario, Table 5) in the liver µmol/l). 
Correspondingly, K
i
 is the inhibition constant for the inhibition by the respec-
tive flavonoids µmol/l). K
m,L-HES
 is the Michaelis–Menten constant for the 
formation of 1ʹ-sulfooxyestragole µmol/l), K
m,L-HEO
 is the Michaelis–Menten 
constant for the formation of 1ʹ-oxoestragole µmol/l), CL
HE
 is the concentra-
tion of 1ʹ-hydroxyestragole in the liver µmol/l), PL
HE
 is the liver/blood partition 
coefficient.
The Michaelis–Menten equations representing the sulfonation or oxidation 
of 1ʹ-hydroxyestragole in the presence of a mixture of noncompetitive inhibi-
tors were derived assuming an additive effect (Results) and that each enzyme 
molecule can combine with no more than one of the inhibitors at a time and 
were as follows:
dAM
HES
/dt = V
max,L-HES
/(1+([I
1
]/K
i1
) +([I
2
]/K
i2
)+([I
3
]/K
i3
)+([I
4
]/K
i4
))*CL
HE
/PL
HE
/
(K
m,L-HES 
+(CL
HE
/PL
HE
))
and
dAM
HEO
/dt = V
max,L-HEO
/(1+([I
1
]/K
i1
) 
+([I
2
]/K
i2
)+([I
3
]/K
i3
)+([I
4
]/K
i4
))*CL
HE
/PL
HE
/(K
m,L-HEO
+(CL
HE
/PL
HE
)) 
where [I
1
], [I
2
], [I
3
], and [I
4
] are the concentrations of the inhibitors: querce-
tin, kaempferol, myricetin, and apigenin in the liver µmol/l), respectively. 
Correspondingly, K
i1,
 K
i2,
 K
i3,
 and K
i4,
 are the inhibition constants for the inhibi-
tion by the respective inhibitors (µmol/l), which were assumed to be equal in 
liver of human and rat.
Data analysis. The maximum velocity (V
max
) and Michaelis–Menten con-
stant (K
m
) for the formation of 7HCS and 1ʹ-oxoestragole were determined 
by fitting the data to the standard Michaelis–Menten equation V  =  V
max
[S]/
(K
m
+[S]), with [S] being the substrate concentration (µM), using the Life 
Science Workbench data analysis toolbox (version 1.1.1, MDL information 
Systems, Inc.). The inhibition constant (K
i
) for each of the selected flavonoids 
was calculated using the Michaelis–Menten equation for noncompetitive inhi-
bition (Vapp
max
=V
max
/(1+([I]/K
i
)), with Vapp
max
 being the apparent V
max
 for the 
reaction in the presence of inhibitor(s) (nmol/min/mg S9 or microsomal pro-
tein), V
max
 being V
max
 for the reaction in the absence of inhibitor(s) (nmol/min/
mg S9 or microsomal protein), and [I] being the inhibitor concentration (µM). 
The Michaelis–Menten equation representing an additive effect for a group of 
noncompetitive inhibitors was derived as follows:
V=V
max
/(1+([I
1
]/K
i1
) +([I
2
]/K
i2
)… +([I
n
]/K
in
))*[S]/(K
m
+[S])
The derivation is based on the assumption that each enzyme molecule can com-
bine with no more than one of the inhibitors at a time. To test whether the 
change in the V
max
 and K
m
 in the presence of the different inhibitors or whether 
the SULT inhibition by the methanolic herb and spice extracts as compared 
with control was significant, a two-sample t-test (one sided) was performed 
after determining variances equality by the Levene’s version of the F test with 
SPSS 15.0 for Windows (SPSS Inc., Chicago, IL).
RESULTS
Inhibition of SULT Activity by Methanolic Herb and 
Spice Extracts
Figure 2 presents the effect of increasing concentrations of a 
series of methanolic herb and spice extracts on SULT activity. 
With the exception of fennel, increasing concentrations of all 
methanolic herb and spice extracts inhibited SULT enzyme 
activity in a dose-dependent manner. The extract from basil 
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was the most potent followed by the extracts from pimento/
allspice, nutmeg, and mace. Extracts from parsley, star anise, 
and cinnamon displayed only moderate SULT inhibition and 
the extracts from tarragon and laurel significantly inhibited 
SULT activity only at the highest concentration tested (100 µg 
extract/ml). Blank incubations, which lacked the cofactor 
PAPS or which lacked the pooled male rat liver S9 fraction, 
did not show any formation of 7HCS (data not shown). This 
indicates that the inhibition of 7HCS formation by the herb and 
spice extracts was fully dependent on the presence of PAPS 
and the S9 fraction containing SULT. Incubations with the 
SULT-inhibitor PCP inhibited SULT activity completely at 
25 µM (data not shown).
Identification of SULT Inhibitors in the Methanolic Herb 
and Spice Extracts
Based on our previous work (Alhusainy et al., 2010), the fla-
vonoid nevadensin was identified as the major SULT-inhibiting 
constituent in the methanolic extract from basil. In the present 
work, based on comparison of HPLC–UV and retention time 
characteristics to HPLC–UV and retention time characteristics 
of commercially available reference compounds, apigenin was 
identified as the second-most potent constituent in the same 
methanolic extract. Among the other most potent methanolic 
herb and spice extracts, the extract from nutmeg was frac-
tionated and the compounds in the most active fractions were 
identified as (+) catechin and (−) epicatechin, whereas in the 
methanolic extract from pimento/allspice, eugenol was identi-
fied as the major SULT inhibitor. Based on the observation that 
in potent extracts flavonoids appeared to be the major SULT 
inhibitors identified, a literature review was made to screen for 
major flavonoids present in alkenylbenzene-containing herbs 
and spices focusing on flavonoids which have been reported 
to be SULT inhibitors (Eaton et  al., 1996; Morimitsu et  al., 
2004). Table 1 presents an overview of the flavonoids reported 
to be present in alkenylbenzene-containing herbs and spices as 
derived from literature and also reported to be SULT inhibitors. 
The overview presented reveals that in a series of 15 selected 
alkenylbenzene-containing herbs and spices, quercetin, kaemp-
ferol, apigenin, and luteolin are among the most abundant fla-
vonoids, and of these flavonoids, quercetin and kaempferol are 
the most widespread in alkenylbenzene-containing herbs and 
spices (Justesen and Knuthsen, 2001).
Selection of SULT-inhibiting Flavonoids to be Tested in 
Subsequent Studies
Given the identification of flavonoids as an important cat-
egory of food-borne SULT inhibitors, and the fact that these 
flavonoids will not only be present in the herbs and spices ana-
lyzed in this study, the selection of the flavonoids to be used in 
the subsequent studies was based on their abundance in the diet 
as a whole. Generally, estimation of the daily dietary flavonoid 
intake is based on the intake of three quantitatively important 
dietary flavonols (quercetin, kaempferol, and myricetin) and 
two quantitatively important dietary flavones (apigenin and 
luteolin) (Hertog et al., 1993a,b). These flavonoids are all pre-
sent in alkenylbenzene-containing herbs and spices, as well as 
throughout the diet, they are all reported to have SULT inhib-
iting potency; the total estimated daily intake (EDI) levels of 
these flavonoids as recorded by different studies varies between 
18.3 ± 3.4 and 25.9 ± 14.5 mg/day (Hertog et al., 1993a, b; Lugasi 
et al., 2003; Mullie et al., 2008). Given these observations, the 
flavonoids quercetin, kaempferol, myricetin, apigenin, luteolin, 
and nevadensin, the latter being the major flavone constitu-
ent in basil (Grayer et al., 2004), were used in our subsequent 
experiments to examine the influence of flavonoids in mixtures 
or individually on the bioactivation of 1ʹ-hydroxyestragole by 
SULT and on the detoxification of 1ʹ-hydroxyestragole via 
FIG. 2. Inhibition of SULT-catalyzed conversion of 7HC into 7HCS by pooled male rat liver S9 fractions in the absence (control) or presence of increasing 
concentrations (10, 25, and 100 µg/ml) of different methanolic herb and spice extracts. 100% 7HCS formation is equal to 1.3 ± 0.1 nmol/min/mg S9 protein. Data 
points represent mean (±SD) of triplicate measurements obtained in independent experiments. An asterisk (*) indicates a significant inhibition compared with the 
incubation without inhibitor (p < 0.05).
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glucuronidation and oxidation using relevant tissue fractions or 
an intact cell model. Figure 3 presents the structure of the fla-
vonoid inhibitors included in the study.
Inhibition of SULT-catalyzed Conversion of 7HC 
Into 7HCS and of Oxidation and Glucuronidation 
of 1ʹ-Hydroxyestragole Into 1ʹ-Oxoestragole and 
1ʹ-Hydroxyestragole Glucuronide by the Selected 
Flavonoids
After identification of major SULT inhibitors present in 
the selected alkenylbenzene-containing herbs and spices 
(nevadensin, quercetin, kaempferol, myricetin, and apigenin), 
initial studies testing the effect of the selected flavonoids 
quercetin, kaempferol, myricetin and apigenin on SULT-
mediated conversion of 7HC into 7HCS and on oxidation 
or glucuronidation of 1ʹ-hydroxyestragole revealed that 
only SULT and oxidation activity appeared to be inhibited. 
Nevadensin was not included in these inhibition studies 
because its effect on sulfonation, glucuronidation, and 
oxidation was already determined in our previous work 
(Alhusainy et  al., 2010). Oxidation and glucuronidation of 
1ʹ-hydroxyestragole were not inhibited by nevadensin to any 
significant extent even at nevadensin concentrations up to 
20 μM (Alhusainy et al., 2010). The effect of the other selected 
flavonoids quercetin, kaempferol, myricetin, and apigenin 
on glucuronidation of 1ʹ-hydroxyestragole was examined by 
adding each flavonoid up to 80 µM together with 1000 µM of 
the substrate 1ʹ-hydroxyestragole in incubations with pooled 
human liver microsomes and the cofactor for glucuronidation 
(UDPGA). None of the flavonoids tested resulted in any 
significant effect on the formation of 1ʹ-hydroxyestragole 
glucuronide. Because the catalytic efficiency for the 
SULT-catalyzed conversion of 7HC into 7HCS and for 
1ʹ-hydroxyestragole into 1ʹ-sulfooxyestragole is higher in the 
liver of rat compared with the liver of human (Alhusainy et al., 
2010; Wang et al., 2006), in vitro incubations for inhibition of 
SULT activity by the selected flavonoids was performed using 
pooled male rat liver S9. Oxidation of 1ʹ-hydroxyestragole 
to 1ʹ-oxoestragole represents a minor metabolic route in 
the liver of male rat as compared with the liver of human 
suggesting that the inhibition of this pathway would hardly 
influence the overall bioactivation of estragole in the liver of 
male rat but may influence the overall metabolism in human. 
Therefore, in vitro incubations for inhibition of oxidation 
of 1ʹ-hydroxyestragole by the selected flavonoids were 
performed in pooled human liver microsomes. In this way, 
the kinetics for inhibition of SULT activity and of oxidation 
of 1ʹ-hydroxyestragole were determined, and the mode of 
inhibition and the respective K
i
 values were defined. Tables 2 
and 3 display the Michaelis–Menten parameters (V
max
 and K
m
) 
and inhibition constants (K
i
) for 7HCS and 1ʹ-oxoestragole 
formation by pooled male rat liver S9 and pooled human 
liver microsomal fractions, respectively, in the presence or 
absence of the flavonoids quercetin, kaempferol, myricetin, 
and apigenin. The apparent V
max
 values for sulfonation 
were lowered significantly (minus 30–33%; p < 0.001 ) 
in the presence of each flavonoid, whereas the apparent K
m
 
values were not statistically significantly different from the 
K
m
 value determined in the absence of each flavonoid. The 
apparent V
max
 values for oxidation of 1ʹ-hydroxyestragole 
were lowered significantly (minus 52–77%; p < 0.001 ) in the 
presence of each flavonoid, whereas the apparent K
m
 values 
were not statistically significantly different from the K
m
 value 
determined in the absence of each flavonoid. These results 
point at a noncompetitive type of inhibition of sulfonation, as 
well as oxidation by each individual flavonoid. Applying the 
Michaelis–Menten equation for noncompetitive inhibition, 
the inhibition constant (K
i
) for SULT inhibition as calculated 
from the data amounted to, respectively, 1.5, 0.6, 11.9, and 
0.7  µM for quercetin, kaempferol, myricetin, and apigenin. 
The inhibition constants (K
i
) for inhibition of the conversion 
of 7HC to 7HCS by the different flavonoids are not expected 
to be significantly different when using 7HC instead of 
1ʹ-hydroxyestragole as a substrate. This is based on the type of 
inhibition that was shown to be noncompetitive meaning that 
only the apparent V
max
 and not the apparent K
m
 of the enzyme 
was found to be affected, which corroborates the assumption 
that flavonoids do not interfere with the substrate binding site 
and exert their inhibiting effect by interaction with another 
site on the enzyme than the site involved in substrate binding 
(Simmons, 1996). In our previous work (Alhusainy et  al., 
2010), the type of SULT inhibition (noncompetitive) and the 
K
i
 (4 nM) for this inhibition by the flavonoid nevadensin was 
similar in pooled male rat and pooled human liver S9 fractions. 
Based on this result, it was assumed that the K
i
 and the type 
of SULT inhibition by the flavonoids quercetin, kaempferol, 
myricetin, and apigenin determined in pooled male rat liver S9 
will also be similar in human liver S9, given that the type of 
inhibition by each of them was also noncompetitive.
The inhibition constant (K
i
) for inhibition of oxidation of 
1ʹ-hydroxyestragole to 1ʹ-oxoestragole by quercetin, kaemp-
ferol, myricetin, and apigenin amounted to 4.5, 1.5, 4.8, and 
6.5 µM, respectively (Table 3).
FIG. 3. Structural formulas of (A) quercetin, (B) kaempferol, (C) myrice-
tin, (D) apigenin, (E) luteolin, and (F) nevadensin, the major SULT inhibitors in 
alkenylbenzene-containing herbs and spices and/or throughout the diet.
180 ALHUSAINY ET AL.
Effect of Selected Flavonoid Mixtures on SULT-catalyzed 
Conversion of 7HC Into 7HCS and on Oxidation of 
1ʹ-Hydroxyestragole Into 1ʹ-Oxoestragole
Given that the diet may contain a variety of SULT inhibitors, 
experiments were performed to assess the effect of combined 
flavonoid exposure on SULT activity, as well as on oxidation of 
1ʹ-hydroxyestragole to 1ʹ-oxoestragole. To this end, a test mixture 
was defined that mimics a realistic dietary flavonoid mixture and 
included four flavonoids which were found to be abundant in 
alkenylbenzene-containing herbs and spices and able to inhibit 
SULT activity, namely, quercetin, kaempferol, apigenin, and 
nevadensin, the latter being previously identified as a potent 
SULT inhibitor present in basil (Alhusainy et  al., 2010). The 
simultaneous addition of quercetin, kaempferol, apigenin, and 
nevadensin at concentrations equal to 0.2K
i
, 0.5K
i
, 1K
i
, 2K
i
, 5K
i
, 
or 10K
i
 of each flavonoid together with 25 µM of the substrate 
7HC lowered the SULT activity in incubations with pooled male 
rat liver S9 (Figure 4). The reduction in the formation of 7HCS 
was similar to the reduction predicted by the Michaelis–Menten 
equation defined for a series of independent noncompetitive 
inhibitors (Figure  4), which verifies our assumption for a 
noncompetitive type of inhibition by each individual flavonoid 
on SULT enzyme activity, as well as an additive interaction 
between the flavonoids in the mixture (Figure 4).
With the exception of nevadensin that had no effect on 
1ʹ-hydroxyestragole oxidation in pooled human liver micro-
somal fractions (Alhusainy et al., 2010), the other SULT inhib-
itors identified in alkenylbenzene-containing herbs and spices, 
namely, quercetin, kaempferol, myricetin, and apigenin, had 
an inhibiting effect on the oxidation of 1ʹ-hydroxyestragole. 
Therefore, incubations for testing the inhibition of conver-
sion of 1ʹ-hydroxyestragole to 1ʹ-oxoestragole by a mixture 
of quercetin, kaempferol, myricetin, and apigenin were per-
formed. Figure  5 shows that the simultaneous addition of 
quercetin, kaempferol, myricetin, and apigenin at concentra-
tions equal to 0.1K
i
, 0.2K
i
, 0.5K
i
, 1K
i
, or 2K
i
, for each flavon-
oid together with 400 µM of the substrate 1ʹ-hydroxyestragole 
reduced the formation of 1ʹ-oxoestragole. The observed inhib-
ition in the formation of 1ʹ-oxoestragole in the presence of 
the flavonoid mixture at concentrations higher than their K
i
 
values matched the predicted values of the derived Michaelis–
Menten formula defined for a series of independent non-
competitive inhibitors, whereas at concentrations lower than 
their K
i
 values, the predicted values were somewhat higher 
than the values actually observed, which may be due to dif-
ferent types of enzymes playing a role in the oxidation of 
FIG. 4. SULT-dependent formation of 7HCS as measured in incubations 
with pooled male rat liver S9 in the presence of increasing concentrations of 
flavonoid mixtures containing quercetin, kaempferol, apigenin, and nevadensin 
at 0K
i
, 0.2K
i
, 0.5K
i
, 1K
i
, 2K
i
, 5K
i
, or 10K
i
 of each flavonoid (), or as predicted 
by our derived Michaelis–Menten equation assuming an additive effect for a 
series of independent noncompetitive inhibitors (solid line).
FIG. 5. Formation of 1ʹ-oxoestragole as measured in incubations with 
pooled human liver microsomes in the presence of increasing concentrations of 
flavonoid mixtures containing quercetin, kaempferol, myricetin, and apigenin 
at 0K
i
, 0.1K
i
, 0.2K
i
, 0.5K
i
, 1K
i
, or 2K
i
 of each flavonoid (), or as predicted by 
our derived Michaelis–Menten equation assuming an additive effect for a series 
of independent noncompetitive inhibitors (solid line).
TABLE 3 
Kinetic Parameters of 1ʹ-Oxoestragole Formation by Pooled 
Human Liver Microsomes in the Absence or Presence of 
Different Flavonoids
Inhibitor
Apparent V
max
(nmol/min/mg 
protein)a
Apparent K
m
(µM)
K
i
b
(µM)
Quercetin
(5 µM)
4.8 ± 1.0* 1046 ± 258 4.6
Kaempferol
(5 µM)
2.3 ± 0.3* 605 ± 69 1.5
Myricetin
(10 µM)
3.5 ± 0.9* 727 ± 292 5.4
Apigenin
(10 µM)
4.0 ± 0.4* 613 ± 66 6.7
aProtein from pooled human liver microsomes.
bCalculated using the Michaelis–Menten equation for noncompetitive inhibi-
tion (Vapp
max
 = V
max
/(1+([I]/K
i
)), where [I] is the flavonoid concentration (µM). 
An asterisk (*) indicates a significant inhibition compared with the incubation 
without inhibitor (p < 0.001).
Note. The control (no inhibitor) V
max
 = 10 ± 1.4 nmol/min/mg microsomal 
protein, and K
m
 = 688 ± 119 µM.
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1ʹ-hydroxyestragole. Thus, other modes of interactions than 
an additive interaction at concentrations lower than K
i
 values 
cannot be excluded. Nonetheless, at all concentrations of the 
flavonoid mixture, the difference between predicted values 
and observed ones was less than twofold. Moreover, a fit to 
the experimental data assuming the inhibition to be competi-
tive instead of noncompetitive matched the experimental data 
worse, showing deviations even at the high concentrations 
and larger variation (up to 2.2-fold) at the lower concentration 
range (data not shown). Therefore, it was concluded that the 
predictions made by the derived formula gives a reasonable 
first approximation.
Effect of Flavonoid Mixtures on Conversion and DNA 
Binding of 1ʹ-Hydroxyestragole in HepG2 Cells
To investigate whether the inhibition of bioactivation 
and detoxification pathways of 1ʹ-hydroxyestragole would 
also be observed in an intact cellular system, cells from 
the human HepG2 hepatoma cell line were exposed to 
1ʹ-hydroxyestragole in the absence or presence of different 
flavonoids and their combinations, followed by detection of 
the level of 1ʹ-hydroxestragole oxidation, glucuronidation, and 
sulfonation, the latter reflected by the formation of the major 
estragole DNA adduct (E-3ʹ-N2-dGuo). Table  4 summarizes 
the different flavonoid mixtures and/or pure flavonoids which 
were investigated in the HepG2 model system. The outcomes 
of these studies will reveal whether selected flavonoids and/or 
their mixtures are able to inhibit SULT-mediated bioactivation 
of 1ʹ-hydroxyestragole in this cellular system, resulting in an 
ultimate shift of metabolism in favor of detoxification at the 
cost of bioactivation. The compounds were not cytotoxic to 
HepG2 cells under the conditions used in these experiments 
as observed by MTT activity measurements (data not shown). 
Fig.  6A reveals that a significant reduction in the formation 
of E-3ʹ-N2-dGuo compared with control (no flavonoid) is 
observed in the human HepG2 cells following co-administration 
of 50 µM of the substrate 1ʹ-hydroxyestragole and 13, 5.4, 2.3, 
1.5, and 0.34 µM of a flavonoid mixture containing quercetin, 
kaempferol, myricetin, apigenin, and luteolin respectively (each 
at a concentration corresponding to its relative contribution 
in the diet, Table  4). E-3ʹ-N2-dGuo formation in the HepG2 
cells is also inhibited significantly by 100  µM of the same 
flavonoids in a mixture (each at 20 µM), by 50 µM kaempferol, 
or by 100  µM quercetin (Fig.  6A). The data indicate that 
the flavonoids are able to pass the cell membrane and exert 
an intracellular effect on SULT mediated bioactivation of 
1ʹ-hydroxyestragole. 
HPLC-UV analysis of the media revealed a significant 
reduction in the formation of 1ʹ-oxoestragole (measured as 
GS-1ʹ-oxoestragole, Fig.  6B) and a significant increase in 
the formation of 1ʹ-hydroxyestragole glucuronide (Fig.  6C). 
Altogether, the data indicate a shift metabolism from sulfona-
tion and oxidation to glucuronidation, which is a detoxification 
pathway for 1ʹ-hydroxyestragole.
PBBK-Model-Based Predictions for Estragole Metabolism 
in the Presence of Selected SULT-inhibiting Flavonoids
Figure  7A illustrates the PBBK-model-based predictions 
for the formation of 1ʹ-sulfooxyestragole in the liver of rat 
and human after co-administration of 0.01 mg/kg bw/day of 
estragole, representing the estragole dose considered relevant 
for human dietary exposure from herbs and spices mainly 
(Smith et  al., 2002), and a mixture of the flavonoids quer-
cetin, kaempferol, myricetin, and apigenin at a total EDI level 
of 20.0 ± 6.3 mg/day (Lugasi et al., 2003; Mullie et al., 2008), 
which corresponds to 0.33 mg flavonoids/kg bw/day for a per-
son of 60 kg. The results presented in Fig. 6A reveal that the 
formation of 1ʹ-sulfooxyestragole in the liver of rat after 24 h 
is predicted to decrease by 0.18%, 1.7%, 8%, and 14.4% com-
pared with control when assuming, respectively, 1%, 10%, 
50%, and 100% uptake of the flavonoid mixture, whereas in 
the liver of human, the formation of 1ʹ-sulfooxyestragole was 
predicted to decrease by, respectively, 0.5%, 5%, 18%, and 
27%. In addition, the possible consequences of consumption of 
estragole together with a flavonoid food supplement containing 
500 mg of quercetin, representing food supplements actually 
available on the market, was also studied. The PBBK model 
predictions indicated that the intake of 500 mg quercetin, which 
corresponds to 8.3 mg querectin/kg bw/day for a person of 
60 kg, together with 0.01 mg/kg bw of estragole may decrease 
TABLE 4 
Flavonvoid Treatments Tested in Human HepG2 Cells Exposed  
to 50 µM of 1′-Hydroxyestragole for 22 h at 37°C
Sample
Flavonoid 
treatments
Concentrations 
in 2.5 mL 
medium Rationale
1 Quercetin 13 µM Based on dietary levels of 12, 
4.6, 2.2, 1.2, and 0.3 mg/day 
(Lugasi et al., 2003; Mullie et al., 
2008) assuming 3 l plasma and 
100% bioavailability
Kaempferol 5.4 µM
Myricetin 2.3 µM
Apigenin 1.5 µM
Luteolin 0.34 µM
2 Quercetin 20 µM High-dose mixture, up to a total 
level of 100 µM, shown to be 
without cytotoxicity
Kaempferol 20 µM
Myricetin 20 µM
Apigenin 20 µM
Luteolin 20 µM
3 Quercetin 100 µM Based on highest dose without 
cytotoxicity given that the level 
in dietary quercetin supplements 
of 500 mg/day, assuming 3 l 
plasma and 100% bioavailability 
would amount to 552 µM
4 Kaempferol 50 µM Kaempferol was the most 
potent flavonoid in inhibiting 
SULT activity and oxidation of 
1ʹ-hydroxyestragole. The con-
centration selected is equal to the 
concentration of the substrate, 
1ʹ-hydroxyestragole
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the formation of 1ʹ-sulfooxyestragole in the liver of rat by 3%, 
23%, 55%, and 69% when assuming 1%, 10%, 50%, and 100% 
uptake of quercetin, and in the liver of human, formation of 
1ʹ-sulfooxyestragole was predicted to decrease by, respectively, 
8.6%, 36%, 56%, and 63% at these levels of quercetin uptake 
(Fig. 7B).
In a third PBBK modeling scenario, the protective effect of 
nevadensin against SULT-mediated bioactivation of estragole 
in consumers of basil was evaluated. Assuming that basil 
contains 0.5% of essential oil (Smith et al., 2002) and that the 
essential oil of basil contains 22.7% of estragole (Sanda et al., 
1998), an EDI of 0.01 mg/kg bw/day of estragole would result 
from an intake of 529 mg basil/day. Based on our previous work 
(Alhusainy et al., 2010), the amount of nevadensin in 529 mg of 
basil is expected to be 0.34 mg, and this would result in an EDI 
FIG. 6. Formation of (A) E-3ʹ-N2-dGuo, (B) 1ʹ-oxoestragole (measured 
as GSH adducts), and (C) 1ʹ-hydroxyestragole glucuronide in HepG2 cells 
exposed for 22 h to 50 µM 1ʹ-hydroxyestragole in the absence or presence of 
a mixture of the following flavonoids: quercetin, kaempferol, myricetin, api-
genin, and luteolin (13, 5.4, 2.3, 1.5, and 0.34 ,µM respectively), 100 µM of the 
same flavonoids in a mixture (each at 20 µM), 50 µM kaempferol, or 100 µM 
quercetin.
FIG. 7. PBBK-model-based predictions for the formation of 
1ʹ-sulfooxyestragole in the liver of rat (black bars) and human (white bars) 
after co-administration of 0.01 mg/kg bw/day of estragole and (A) a mixture 
of flavonoids at their EDI levels including 12 mg/day of quercetin, 4.6 mg/day 
of kaempferol, 2.2 mg/day of myricetin, and 1.2 mg/day of apigenin; (B) quer-
cetin at a dose level present in food supplements amounting to 500 mg/day; or 
(C) nevadensin at 0.34 mg/day, representing the dose level resulting from intake 
of 529 mg of basil, which is the amount of basil resulting in 0.01 mg/kg bw/
day of estragole (Alhusainy et al., 2010; Sanda et al., 1998; Smith et al., 2002).
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for nevadensin of 0.0057 mg/kg bw/day for a person of 60 kg. At 
an estragole dose of 0.01 mg/kg bw/day and a nevadensin intake 
of 0.0057 mg/kg bw/day, the formation of 1ʹ-sulfooxyestragole 
in the liver of rat is predicted to decrease by 0.77%, 7%, 26%, 
and 40% compared with control, whereas in the liver of human, 
the formation of 1ʹ-sulfooxyestragole was predicted to decrease 
by 3.5%, 25%, 56%, and 68% when assuming, respectively, 
1%, 10%, 50%, and 100% uptake of nevadensin (Fig. 7C).
Finally, it is worth noting that even when the concentration 
of estragole was increased 1000-fold keeping the concentra-
tions of the SULT-inhibiting flavonoids at the values defined 
in Table  5, the percentage inhibition of 1ʹ-sulfooxyestragole 
formation remains the same as obtained at the 1000-fold lower 
dose of estragole. This is a characteristic of noncompetitive 
inhibition, for which the level of inhibition depends only on the 
dose of the inhibitors (Simmons, 1996).
DISCUSSION
The alkenylbenzene estragole is an important natural con-
stituent of herbs and spices. However, several studies have 
shown both genotoxic and carcinogenic properties for this com-
pound in rodents (Drinkwater et al., 1976; Miller, 1983). These 
experiments were performed using the pure compound dosed 
by gavage in high doses, whereas in herbs and spices, estragole 
is present in relatively lower amounts together with other con-
stituents in a food matrix, which can influence its biochemical 
fate. The present study reports that methanolic extracts from 
different alkenylbenzene-containing herbs and spices were 
able to inhibit SULT activity involved in the formation of the 
proximate hepatocarcinogen 1ʹ-sulfooxyestragole. Flavonoids 
including nevadensin, quercetin, kaempferol, myricetin, and 
apigenin were the major constituents responsible for this inhib-
ition of SULT activity with K
i
 values in the nano- to micromolar 
range. Apart from SULT inhibitors present in herbs and spices 
and identified in the present study, the regular human diet is 
rich in other SULT inhibitors ranging from a number of natural 
dietary chemicals, such as polyphenols (Eaton et al., 1996), to 
a number of food additives such as (±)-catechin, (+)-catechin, 
4-chlorobenzoic acid, aspartame, benzoic acid, erythrosine, 
gallic acid, octyl gallate, p-hydroxybenzoic acid, propyl gall-
ate, protocatechuic acid, saccharin, tannic acid, tartrazine, and 
vanillin, which have all been shown to be capable to inhibit 
the sulfonation of a number of xenobiotics and endobiotics 
in human liver cytosol to varying extents (Bamforth et  al., 
1993). A  great volume of literature data supports the plausi-
bility of noncompetitive inhibition of sulfonation of various 
substrates by different flavonoids such as quercetin, genistein, 
(+)-catechin, kaempferol, apigenin, and diadzein (Ghazali and 
Waring, 1999; Mesía-Vela and Kauffman, 2003; Walle et al., 
1995). The various flavonoids tested in this study were also 
shown to be able to significantly inhibit estragole DNA-adduct 
formation in human HepG2 cells exposed to the proximate car-
cinogen 1ʹ-hydroxyestragole (50% reduction compared with 
control) even at concentrations as low as 25 µM of the flavon-
oid mixture. The results of the present work also show that at 
levels of flavonoids sufficient to inhibit SULT activity, they can 
also inhibit the oxidation of 1ʹ-hydroxyestragole, which is the 
major phase-II pathway of 1ʹ-hydroxyestragole in the liver of 
human. Additional results of the present study revealed that 
in the human HepG2 cells exposed to 1ʹ-hydroxyestragole in 
the presence of flavonoids, reduction in the activity of sulfon-
ation and oxidation results in a metabolic shift toward glu-
curonidation, which serves as a detoxification pathway for 
1ʹ-hydroxyestragole.
In a next step, the kinetics for SULT inhibition were 
incorporated in the PBBK models for estragole in rat and human 
to predict the effect of co-exposure to estragole and (mixtures 
of) the different flavonoids on the bioactivation in vivo. The 
PBBK model-based predictions indicate that the reduction of 
estragole bioactivation in rat and human by co-administration 
of the flavonoids is dependent on whether the intracellular 
liver concentrations of the flavonoids can reach their K
i
 values 
determined in the present study. For example, high intake levels 
of SULT inhibitors (e.g. quercetin) at levels present in food 
TABLE 5 
Input Data for PBBK Models Representing Three Possible Intake 
Scenarios of Flavonoids and Estragole at 0.01 mg/kg bw/day
Scenario
Constant (L)a Input PBBK
(Flavonoid:estragole) [Flavonoid] = CL
E
 × L × f
EDI of flavonoidsb
Quercetin (4 × 10−5 mol/
day)
9.8 [Quercetin] = CL
E
 × 
9.8 × f
Kaempferol (1.6 × 10−5 
mol/day)
4.0 [Kaempferol] = CL
E
 × 
4.0 × f
Myricetin (7 × 10−6 mol/
day)
1.7 [Myricetin] = CL
E
 × 
1.7 × f
Apigenin (4.4 × 10−6 mol/
day)
1.1 [Apigenin] = CL
E
 × 
1.1 × f 
Quercetin tablets 
(0.002 mol/day)
408 [Quercetin] = CL
E
 × 
408 × f
Nevadensin (1.1 × 10−6 
mol/day)c
0.25 [Nevadensin] = CL
E
 × 
0.25 × f
Note. CL
E
 is the concentration of estragole in the liver (µmol/l), L is a constant 
that is determined based on the corresponding intake scenario and f is the molar 
ratio between estragole and each flavonoid that varies from 0 (no SULT inhibitors 
uptake into liver) to 1 (representing 100% uptake of a flavonoid into the liver).
aConstant (L) is calculated as the ratio between the EDI of a flavonoid and the 
EDI of estragole of 0.01 mg/kg bw/day (Smith et al., 2002), which is equivalent 
to 4.1 × 10−6 mol/day given a molecular weight for estragole of 148 g/mol and 
assuming a body weight of 60 kg.
bBased on Lugasi et al., 2003; Mullie et al., 2008.
cAssuming that basil contains 0.5% of essential oil (Smith et al., 2002) and 
that the essential oil of basil contains 22.7% of estragole (Sanda et al., 1998), an 
EDI of 0.01 mg/kg bw/day of estragole would result from a 529 mg basil/day. The 
amount of nevadensin in 529 mg of basil is expected to result in a daily intake 
of 0.34 mg/day or 1.1 × 10-6 mol/day for a 60 kg person (Alhusainy et al., 2010). 
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supplements currently available on the market might result in 
significant inhibition of the formation of 1ʹ-sulfooxyestragole 
even at 10% uptake of the flavonoid. Interestingly, for human liver, 
a dose of nevadensin of only 0.34 mg/day was predicted to result 
in comparable inhibition of 1ʹ-sulfooxyestragole formation as a 
dose of quercetin of 500 mg/day (Figs. 6B and C). This clearly 
illustrates that although nevadensin is not a major flavonoid 
constituent in the diet, its contribution to the SULT mediated 
modulation of estragole is already achieved at relatively lower 
dose levels due to its K
i
 value of 4 nM (Alhusainy et al., 2010), 
which is 2–3 orders of magnitude lower than that for other 
flavonoids. Furthermore, the inhibitory effect of nevadensin in 
vivo may also be more easily achieved than that of the other 
flavonoids because nevadensin is a methylated flavonoid, and 
methylated flavones such as nevadensin have been demonstrated 
to be more metabolically stable and have a higher intestinal 
absorption than their unmethylated analogues increasing the 
oral bioavailability of methylated flavones compared with their 
unmethylated analogues (Wen and Walle, 2006).
In this context, it is also of interest to take into account the 
reported intracellular and circulating concentrations of the dif-
ferent flavonoid-type SULT inhibitors. Mean plasma levels of 
quercetin, for example, reached 7.6 µM in human volunteers 
after consuming a supplement of 160 g stewed and homoge-
nized onions, which provided 331 µmol of quercetin glucosides 
(Graefe et al., 2001), a plasma level which is sufficient to inhibit 
SULT activity giving a K
i
 for quercetin-mediated SULT inhibi-
tion of 1.5 µM as determined in the present study. Moreover, 
after a single oral dose of 200 mg/kg bw of Chrysanthemum 
morifolium extract to rats apigenin reached maximum plasma 
levels of 16 µM (Chen et al., 2007). Clearly, plasma levels of 
quercetin and apigenin can reach levels higher than their K
i
. Data 
on human plasma levels of other flavonoids tested in the present 
study are lacking. However, plasma levels for other flavonoids, 
namely, the isoflavones genistein and daidzein, may exceed 
0.5 µM in women who eat a traditional Japanese diet (Uehara 
et al., 2000) and may even reach 1 µM in individuals consum-
ing some dietary supplements (Gooderham et al., 1996), both 
levels are sufficient to inhibit SULT1A1 and SULT1EI signifi-
cantly given the IC
50
 for inhibition of SULT1A1 and SULT1EI 
by genistein of 0.5 and 1 µM, respectively (Harris et al., 2004). 
Moreover, plasma levels of other flavonoids, such as hesperetin, 
may reach 1–3 µM after ingestion of large amounts of fruit and 
vegetables (Erlund et al., 2002), which are concentrations suf-
ficient to inhibit both SULT1A1 and SULT1E1 (Harris et al., 
2004). It is important to note, however, that in vivo flavonoids 
undergo extensive conjugation to their corresponding glucu-
ronic acid and sulfate conjugates, and that in most in vivo stud-
ies, flavonoids are measured after deconjugation. Therefore, the 
reported plasma concentrations may reflect total flavonoid con-
centration in the conjugated and unconjugated forms instead of 
the concentrations of the aglycon. This raises the question if in 
these conjugated forms the flavonoids are still able to interact 
with SULTs. In this regard, it is worth to note that conjugated 
metabolites of flavonoids can retain the biological activity of the 
parent compound (Harris et al., 2004). This is highly depend-
ent on the molecular site of conjugation. Moreover, studies in 
which cells in vitro were exposed to glucuronidated and sul-
fonated conjugates of quercetin demonstrated that within the 
cells, the flavonoid was no longer conjugated due to efficient 
extra- and/or intracellular deconjugation (Lee-Hilz et al., 2008). 
Another issue of interest is if these flavonoids reported in litera-
ture can inhibit the same SULT isoforms which are involved in 
the sulfonation of the substrate 1ʹ-hydroxyestragole, which have 
so far not been identified.
Several PBPK models have been developed and investigated 
chemical interactions at the level of metabolic competition 
(Dobrev et al., 2002; El-Masri et al., 1996a,b; Krishnan et al., 
2002). These models have identified thresholds for exposure, 
below which competitive inhibition is not expected. In this 
regard, we have shown in our paper that plasma levels of the 
different flavonoids can reach levels sufficiently high to inhibit 
SULT activity and in a noncompetitive way.
Finally, it is important to note that the PBBK model analysis 
of the effect of the inhibitors on estragole bioactivation in vivo 
as presented is a fist approximation. More refined models could 
take into account (1) submodels for the ADME characteristics 
of the individual flavonoids and/or (2) nonadditive modes of 
interactions for the flavonoids in mixture on the conversion 
of 1ʹ-hydroxyestragole to 1ʹ-oxoestragole which better fit the 
experimental in vitro data for this inhibition. However, devel-
opment of such refined models was beyond the scope of the 
present study.
In conclusion, dietary flavonoids may modulate the bioac-
tivation and thus the ultimate cancer risk posed by estragole 
provided that the physiological liver concentrations of the 
inhibitors reach their K
i
 values. Whether in vivo levels of flavo-
noids can reach their K
i
 values and whether conjugated forms 
of the flavonoids can still inhibit SULT activity are important 
issues that need further investigation. Overall, an in vivo modu-
lation for estragole bioactivation is highly plausible given the 
facts that (1) SULT inhibitors are abundant in the diet, (2) their 
inhibition constants (K
i
) for SULT activity are in the nano- to 
micromolar range, and (3) their combined effect on SULT 
enzyme activity was shown to be additive. If the PBBK-based 
predicted data can be validated in vivo, which is an important 
issue for future research, this would imply that the likelihood 
of bioactivation and subsequent adverse effects might be lower 
when alkenylbenzenes are consumed in a matrix of food items 
containing SULT inhibitors than what would be expected on 
the basis of experiments using alkenylbenzenes as pure com-
pounds. The safety of alkenylbenzene-containing botanicals 
could consequently be judged and regulated on the basis of the 
EDIs of the different alkenylbenzenes compared with the EDI 
of the different respective SULT inhibitors which are present in 
the diet. Further research investigations are directed at investi-
gating efficiency of SULT inhibitors in reducing-DNA adduct 
formation and the subsequent carcinogenic risk in vivo.
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